Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers

Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers

PURPOSE Larotrectinib is a highly selective and CNS-active tropomyosin receptor kinase (TRK) inhibitor that has demonstrated efficacy across TRK fusion–positive cancers, regardless of the tumor type. The aim of this study was to assess the efficacy and safety of larotrectinib in patients with TRK fu...

Full description

Bibliographic Details
Main Authors: Brega, N. (Author), Dima, L. (Author), Drilon, A. (Author), Kummar, S. (Author), Lassen, U.N (Author), Leyvraz, S. (Author), Lin, J.J (Author), Liu, Y. (Author), Moreno, V. (Author), Norenberg, R. (Author), Patel, J.D (Author), Rosen, L. (Author), Shen, L. (Author), Solomon, B. (Author), Tan, D.S.W (Author)
Format: Article
Language:English
Published: American Society of Clinical Oncology 2022
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items